All Stories

  1. Estimation of the indirect costs associated with chronic rhinosinusitis with nasal polyposis in Spain: an analysis from a societal perspective
  2. What Patients With Asthma Share When No One Listens: Multimethod Observational Study of Patient Narratives on Reddit
  3. Investigating human IgE antibody interactions with pollen-derived sporopollenin biopolymers: Immunoreactivity profiling for the rational design of structurally robust and biocompatible biomaterials
  4. Minocycline‐Induced Delayed Dermographism With Tolerance to Doxycycline
  5. Evaluation of Real-World Quality of Asthma Care According to the Spanish Consensus Protocol: The AsmaNET Project (ESR-20-20897)
  6. Gestión eficiente de agendas de asma grave
  7. Stability of Fractional Exhaled Nitric Oxide and Its Relationship With Exacerbation in Patients Aged 6 Years or Older With Uncontrolled, Moderate-to-Severe Asthma
  8. What Patients With Asthma Share When No One Listens: Multimethod Observational Study of Patient Narratives on Reddit (Preprint)
  9. Measuring Food-Specific-IgG4s With Milk
  10. A RETROSPECTIVE REAL-WORLD STUDY OF PHADIATOP USE AND ITS IMPACT ON REFERRALS TO ALLERGY SPECIALISTS IN A HEALTH AREA
  11. TSLP and TSLPR Expression Levels in Peripheral Blood as Potential Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps
  12. Tslp and Tslpr Expression Levels in Peripheral Blood as Potential Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps
  13. Evaluation Checklist for the Multidisciplinary Approach to Patients with Asthma or Suspected Asthma in United Airway Disease
  14. Cough severity visual analog scale scores and quality of life in patients with refractory or unexplained chronic cough
  15. Assessment of sIgE to rLep d 2 for detecting Lepidoglyphus destructor sensitization
  16. The Role of the Gut and Airway Microbiota in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review
  17. Assessment of sIgE to rLep d 2 for Detecting Lepidoglyphus destructor Sensitization
  18. Delabeling of allergy to beta-lactam antibiotics in hospitalized patients: a prospective study evaluating cost savings
  19. An Exceptional Case of Recall Phenomenon to Hypersensitivity to Amoxicillin
  20. Contact Palpebral Dermatitis and Conjunctivitis Due to Delayed Hypersensitivity to Timolol
  21. Impact of the ERS/ATS 2021 guidelines for lung function interpretation on assessing the response to biologics in asthma
  22. Burden of refractory and unexplained chronic cough on patients’ lives: a cohort study
  23. Transcriptomics reveals new regulatory mechanisms involved in benralizumab response
  24. Correspondence regarding the paper “Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R. Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R....
  25. Interleukin 5 Receptor Subunit Alpha Expression as a Potential Biomarker in Patients with Nasal Polyposis
  26. Role of Different Health Care Professionals in the Management of Asthma Patients: The GEMA-FORUM IV Task Force
  27. Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature
  28. ALERGODATA: Sentinel registry of health outcomes in allergic patients treated with biological therapies from specialized allergology clinics in Spain
  29. Characteristics and Management of Patients with Refractory or Unexplained Chronic Cough in Outpatient Hospital Clinics in Spain: A Retrospective Multicenter Study
  30. Avances en el manejo del asma difícil de tratar y asma grave
  31. A Prospective Study of Costs Associated With the Evaluation of Allergic Reactions to Radiological Contrast Media
  32. Quantitative and qualitative methods of evaluating response to biologics in severe asthma patients: Results from a real-world study
  33. Sensitization Phenotypes in Immediate Hypersensitivity to Cephalosporins: A Cluster Analysis Study
  34. Severity and duration of allergic conjunctivitis: are they associated with severity and duration of allergic rhinitis and asthma?
  35. RNY3 modulates cell proliferation and IL13 mRNA levels in a T lymphocyte model: a possible new epigenetic mechanism of IL-13 regulation
  36. Management of United Airway Disease Focused on Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review
  37. Response to monoclonal antibodies in asthma: definitions, potential reasons for failure and therapeutic options for suboptimal response
  38. Changes in Sensitization Patterns in the Last 25 Years in 619 Patients with Confirmed Diagnoses of Immediate Hypersensitivity Reactions to Beta-Lactams
  39. Cluster Subanalysis of Patients With Severe Asthma Who Responded to Omalizumab
  40. Environmental drivers of the seasonal exposure to airborne Alternaria spores in Spain
  41. Dupilumab: A Review of Present Indications and Off-Label Uses
  42. Polymorphisms in Human IL4, IL10, and TNF Genes Are Associated with an Increased Risk of Developing NSAID-Exacerbated Respiratory Disease
  43. Hypersensitivity to Gadolinium-Based Contrast Media
  44. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
  45. Effects of Therapeutic Antibodies on Gene and Protein Signatures in Asthma Patients: A Comparative Systematic Review
  46. Patterns of Cross-Reactivity in Patients With Immediate Hypersensitivity Reactions to Gadobutrol
  47. Integration of in vitro allergy test results and ratio analysis for the diagnosis and treatment of allergic patients (INTEGRA)
  48. PTGDR2 Expression in Peripheral Blood as a Potential Biomarker in Adult Patients with Asthma
  49. Delayed Reaction to Gadobutrol in a Nurse With Myocarditis After SARS-Cov-2 Infection
  50. Genetics and Epigenetics of Nasal Polyposis: A Systematic Review
  51. Reply to “Delayed hypersensitivity reactions to piperacillin-tazobactam”
  52. ARADyAL: The Spanish Multidisciplinary Research Network for Allergic Diseases
  53. Increased TPSAB1 Copy Number in a Family With Elevated Basal Serum Levels of Tryptase
  54. Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement
  55. A Comprehensive Prospective Study of the Costs Associated With Evaluation of ß-Lactam Allergy
  56. Molecular Analysis of IL-5 Receptor Subunit Alpha as a Possible Pharmacogenetic Biomarker in Asthma
  57. Real‐life study in non‐atopic severe asthma patients achieving disease control by omalizumab treatment
  58. Pollen-Induced Allergic Asthma and Rhinoconjunctivitis: Differences in Outcome Between Seasonal and Nonseasonal Exposure to Allergens Under Real-Life Conditions (The LANDSCAPE Study)
  59. Analysis of the Costs Associated With the Elective Evaluation of Patients Labelled as Allergic to Beta-Lactams or Nonsteroidal Antiinflamatory Agents
  60. Precision Medicine in House Dust Mite-Driven Allergic Asthma
  61. Usefulness of an Artificial Neural Network in the Prediction of β-Lactam Allergy
  62. Sensitization phenotypes in immediate reactions to piperacillin-tazobactam
  63. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.
  64. A Prospective Study of Costs Associated with the Evaluation of β-Lactam Allergy in Children
  65. Cheilitis Associated With Sensitization to Penicillium notatum in a Clarinetist
  66. Urban atmospheric levels of allergenic pollen: comparison of two locations in Salamanca, Central-Western Spain
  67. Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment
  68. <p>FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma</p>
  69. COVID-19, asthma, and biological therapies: What we need to know
  70. Promoter Genotyping and mRNA Expression – Based Analysis of the PTGDR Gene in Allergy
  71. Genetics and Epigenetics of Atopic Dermatitis: An Updated Systematic Review
  72. Atopy Can Be an Interfering Factor in Genetic Association Studies of ß-Lactam Allergy
  73. A prospective study of costs associated to the evaluation of non‐steroidal anti‐inflammatory hypersensitivity reactions
  74. Severe asthma phenotypes in patients controlled with omalizumab: A real-world study
  75. Relationship between CRTH2 mRNA expression in peripheral blood and IgE and eosinophil levels in adult patients with asthma
  76. Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies
  77. YRNAs overexpression and potential implications in allergy
  78. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018
  79. Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response
  80. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma
  81. PTGDR expression is upregulated through retinoic acid receptors (RAR) mechanism in allergy
  82. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm
  83. Tolerability of iobitridol in patients with non-immediate hypersensitivity reactions to iodinated contrast media
  84. A case report of fixed drug eruption caused by several drugs because of cross-reactivity and co-sensitization
  85. Adherence to Anaphylaxis Guidelines: Real-World Data From the Emergency Department of a Tertiary Hospital
  86. Dupilumab: A New Paradigm for the Treatment of Allergic Diseases
  87. Resolution of Type IV Hypersensitivity After Bone Marrow Transplantation
  88. Cluster Analysis Identifies 3 Phenotypes within Allergic Asthma
  89. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen
  90. Consensus document on dog and cat allergy
  91. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  92. Phenotypes related with clinical improvement of omalizumab-treated patients in routine clinical practice. FENOMA Study
  93. Economic costs of severe asthma in omalizumab-treated patients. FENOMA Study
  94. Pharmacogenetics and the treatment of asthma
  95. Reproduction of the atopic march in an adult after allogeneic bone marrow transplantation from an atopic sibling
  96. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies
  97. Acute generalized exanthematous pustulosis (AGEP) induced by azithromycin
  98. Allergic respiratory disease: Different allergens, different symptoms
  99. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study
  100. Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study
  101. Performance in real life of the European Network on Drug Allergy algorithm in immediate reactions to beta-lactam antibiotics
  102. Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study
  103. Predictive models in drug allergy: An appropriate patient selection is needed
  104. Retinoic Acid Modulates PTGDR Promoter Activity
  105. Filaggrin gene mutations and new SNPs in asthmatic patients: a cross-sectional study in a Spanish population
  106. Relationship between respiratory and food allergy and evaluation of preventive measures
  107. Comparison of Pollen Levels Between 2 Pollen Traps in Salamanca, Spain
  108. Effectiveness of omalizumab in severe solar urticaria
  109. Applications of Molecular Genetics to the Study of Asthma
  110. Analysis of FOXP3 gene in children with allergy and autoimmune diseases
  111. Genome-wide association studies (GWAS) and their importance in asthma
  112. First case of airborne-induced anaphylaxis triggered by fruit
  113. Implications of cytokine genes in allergic asthma
  114. Genome-wide expression profiling of B lymphocytes reveals IL4R increase in allergic asthma
  115. Olive, grass or both? Molecular diagnosis for the allergen immunotherapy selection in polysensitized pollinic patients
  116. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test® no-call in the clinical setting
  117. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease
  118. Diagnostic and therapeutic approaches in respiratory allergy are different depending on the profile of aeroallergen sensitisation
  119. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy
  120. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain
  121. Bilastine for the treatment of urticaria
  122. Tryptase: Genetic and functional considerations
  123. Reply
  124. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study
  125. Aeroallergen Sensitization Influences Quality of Life and Comorbidities in Patients with Nasal Polyposis
  126. Reply
  127. The impact of allergic rhinitis on symptoms, and quality of life using the new criterion of ARIA severity classification
  128. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib
  129. Measurement of asthma control according to global initiative for asthma guidelines: a comparison with the asthma control questionnaire
  130. Epigenetic changes in B lymphocytes associated with house dust mite allergic asthma
  131. PTGDR gene in asthma: a functional, genetic, and epigenetic study
  132. Immediate allergic reactions to β-lactams: Diagnostic accuracy of skin tests
  133. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study
  134. Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant
  135. Airborne pollen calendar of Salamanca, Spain, 2000–2007
  136. Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitis
  137. Immunological aspects of nonimmediate reactions to β-lactam antibiotics
  138. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study
  139. Do genetic factors determine atopy or allergy?
  140. Epigenetic aspects of the allergic diseases
  141. Component‐resolved diagnosis of pollen allergy based on skin testing with profilin, polcalcin and lipid transfer protein pan‐allergens
  142. Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study
  143. Recurring eczema during pregnancy and after delivery due to sensitization caused by an ultrasound gel
  144. Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts
  145. A new PTGDR promoter polymorphism in a population of children with asthma
  146. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients
  147. Hypersensitivity reactions to cephalosporins
  148. Molecular Analysis of Activation-Induced Cytidine Deaminase Gene in Immunoglobulin-E Deficient Patients
  149. Therapeutic Applications of Antisense Oligonucleotides in Asthma and Allergy
  150. Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis: The ESPRINT Questionnaire
  151. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol
  152. Proteomic approaches for identifying new allergens and diagnosing allergic diseases
  153. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items
  154. Prevention of allergic diseases
  155. Promoter genetic variants of prostanoid DP receptor (PTGDR) gene in patients with asthma
  156. Interleukin-4 (IL4) and Interleukin-4 receptor (IL4RA) polymorphisms in asthma: a case control study
  157. El polimorfismo Q576R del gen IL4RA se asocia con valores elevados de IgE total en pacientes con antecedentes familiares de atopia
  158. Analysis of the leukotriene C4 synthase A−444C promoter polymorphism in a Spanish population
  159. Tick-bite-induced anaphylaxis in Spain
  160. Infección vírica y asma: mecanismos inmunológicos
  161. Interacción de isoniazida con alimentos
  162. Anaphylactic reaction to ranitidine
  163. Cross‐reactivity between quinolones
  164. Occupational protein contact dermatitis from herring
  165. Fixed eruption caused by ciprofloxacin with cross‐sensitivity to norfloxacin
  166. Hypersensitivity to trimethoprim
  167. Urticaria from caffeine